Kyverna Therapeutics Appoints Former Ironwood CFO Gregory Martini as New CFO
KYTX has more than doubled off its 52-week low of $2.06.
Summary
Kyverna Therapeutics appointed Gregory Martini, a veteran biopharma finance leader, as its new CFO, signaling a strategic move to bolster financial leadership as the company approaches commercialization of its lead therapy.
Key Events · Executive and Board Changes · KYTX
-
New CFO Appointment
Gregory Martini, former CFO of Ironwood Pharmaceuticals, has been appointed as Kyverna's Chief Financial Officer, effective May 18, 2026. He will also serve as principal financial and accounting officer.
-
Strategic Hire for Commercialization
Martini brings extensive experience in financial strategy and commercial-stage growth, which is crucial as Kyverna advances its lead therapy, miv-cel, toward potential regulatory approval and market launch.
-
Significant Equity Incentive
Martini received an inducement grant of options to purchase 325,000 shares of common stock, valued at approximately $3.04 million based on the current stock price.
-
Smooth Leadership Transition
Outgoing CFO, Marc Grasso, M.D., will continue as a strategic advisor through August 1, 2026, to ensure a seamless handover. The company stated his departure was not due to any disagreements.
Analysis · KYTX · Life Sciences
Kyverna Therapeutics has appointed Gregory Martini, former CFO of Ironwood Pharmaceuticals, as its new Chief Financial Officer. This strategic hire brings significant financial leadership and commercial-stage experience as Kyverna prepares for the potential approval and launch of its lead therapy, miv-cel. The outgoing CFO, Marc Grasso, will transition to an advisory role, ensuring continuity. Martini's compensation includes a substantial equity grant of 325,000 stock options, aligning his incentives with long-term company performance.
At the time of this filing, KYTX was trading at $9.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $576.9M. The 52-week trading range was $2.06 to $13.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.